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ABSTRACT 
Every year, 600 people in Sweden develop MS, making it the second most common 
cause of disability (after accidents) in young adults. The pathophysiology is 
characterized by inflammation of the central nervous system and impaired neuronal 
signaling. Although the cause of MS remains elusive, important environmental and 
genetic contributors to disease risk have been identified. In order to develop better 
treatment strategies these risk modifying elements need to be functionally understood 
in the context of MS. Since the vast majority of currently known genetic and 
environmental factors increasing MS susceptibility have only been discovered in the 
past 5 years, now is the time to elucidate their biological foundation. This thesis, as the 
title suggests, focuses on the genetics of MS and how it impacts pathology. In time and 
content, it straddles the shift between searching for genetic associations (paper I), and 
understanding their clinical and biological implications (papers II-IV).  
 
The main scientific objective of my PhD project was to characterize the association 
between the gene encoding the IL-7 receptor α-chain (IL7R) and MS susceptibility. 
First, we show that IL7R genotype does not impact clinical characteristics of MS such 
as disease severity or age at onset (paper II). This suggests that the link to MS 
susceptibility is indeed due IL7R’s influence on disease triggering events rather than an 
effect of altered clinical manifestation. In paper III we confirm previous reports that the 
MS associated allele (IL7R*C) causes increased expression and production of an 
alternatively spliced, soluble receptor isoform (sIL7Rα). We show that this isoform has 
intermediate affinity for IL-7, but contrary to membrane bound IL7Rα, does not bind 
TSLP. Despite competing with cell associated IL7Rα, sIL7Rα prolongs and potentiates 
IL-7’s bioactivity both in vitro and in vivo by limiting excessive IL-7 consumption. 
Furthermore, MS patients homozygous for IL7R*C have a 2-fold increase in plasma 
IL-7 levels, consistent with decreased IL-7 consumption as a result of higher sIL7Rα. 
In order to further map the interface between MS and IL-7 we went on to screen 
patients’ serum IL-7 levels under different treatment regimens (paper IV). We found 
that MS patients receiving IFNβ therapy have increased serum IL-7 levels compared to 
untreated patients and healthy controls. The elevated IL-7 levels are coupled with both 
lower peripheral blood lymphocyte counts during IFNβ treatment, and reduced IL7Rα 
expression on those lymphocytes. Considering the stable rate at which IL-7 is typically 
produced, and our data supporting reduced IL-7 consumption, the increase in serum IL-
7 is likely a product of slower depletion rather than increased production. Since IL-7 is 
an immune stimulatory cytokine associated with several autoimmune diseases, 
therapeutic modulation of this axis may improve clinical outcomes of MS patients, 
particularly for those receiving IFNβ treatment. 
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1 INTRODUCTION 
 
1.1 MULTIPLE SCLEROSIS 
 
Multiple sclerosis (MS) is a chronic, heterogeneous disease of the central nervous 
system (CNS), characterized by local inflammation and myelin destruction in the brain 
and spinal cord. The name multiple sclerosis refers to the characteristic sclerotic 
plaques, which appear as a result of local inflammation in the CNS.  This inflammation 
is mainly due to leukocyte infiltration of the brain and spinal cord, and leads to targeted 
destruction of the myelin sheath (1). CNS myelin is made up of cellular membrane 
from oligodendrocytes and facilitates neuronal communication through axons by 
providing insulation. This insulation ensures rapid and protected carriage of action 
potentials through the axon. As the disease progresses and damage to the 
oligodendrocytes increases, demyelination of neuronal axons worsens and cutting of 
axons and neuronal atrophy occur with increasing frequency (2). The symptoms of MS 
can vary widely based on what part of the brain is affected by demyelination. Typically 
the initial phase is characterized by a relapsing-remitting disease course where bouts of 
worsened disability and recovery follow each other (RRMS). Ultimately, a progressive 
accumulation of neurological disability ensues (secondary progressive MS - SPMS). 
The remaining group (10-15% of patients) has a primary progressive, bout-free disease 
course and typically a later disease onset (PPMS; Figure 1).  
 
A person’s first MS-like neurological symptom is usually referred to as a Clinically 
Isolated Syndrome (CIS). For an MS diagnosis to be made according to current 
standards (McDonald criteria) a second event, separate in time or space is required (3). 
A recent report looking at the risk of developing chronicity and hence MS within 20 
years of presenting with CIS was 63% (4). The risk of MS went up to 82% if the CIS 
was accompanied by abnormal magnetic resonance imaging (MRI) findings. Although 
a clear majority of CIS cases eventually go on to develop MS, these reports (4-6) 
highlight the fact that not everyone undergoing an MS-like CIS end up with an MS 
diagnosis (Figure 1). Whether clinically indistinguishable pathophysiological 
differences between CIS events determine who develops MS and who does not remains 
to be determined. An alternative possibility is that the chronicity of MS is established 
by separate mechanisms than those triggering the initial event of neuro-inflammation, 
i.e. physiologically identical CIS events could lead to different outcomes. If this is the 
case, it indicates that the initial loss of self-tolerance is controlled by different 
mechanisms than the formation of a stable myelin-reactive immunological memory.  
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Figure 1: Common disease phenotypes of MS and CIS. (A) In most cases, a CIS later develops into 
relapsing-remitting disease which with time develops into secondary progressive MS. (B) 10-15% of MS 
patients present with a bout free phenotype called primary progressive MS. (C) 20-40% of CIS cases 
never develop MS. 
 
The average age at RRMS onset is around 30 years. Life expectancy is not severely 
impacted by MS, but patients do have a slight increase in mortality (7). This increase is 
primarily accounted for by “death due to MS” rather than increased death due to co-
morbidities. Cancer for example seems convincingly less likely to be the cause of death 
of an MS patient compared to the general population, perhaps due to increased immune 
reactivity in some MS patients (7, 8). MS is the most common neurodegenerative 
disorder in Sweden with a prevalence of around 1 in 520. Women are over two times 
more likely (prevalence in Sweden ≈ 1 in 380) than men (1 in 880) to develop disease 
(9). Although longevity is not severely affected, MS poses a huge burden both to the 
affected individual and his or her family-members in terms of reduced quality of life, as 
well as to society due to the high cost of treatment (10).  
 
1.1.1 Who Gets MS? 
 
The first evidence of increased familial recurrence of MS was reported over 100 years 
ago (11). Since then, it has been shown through numerous epidemiological studies that 
MS is a complex disease with both environmental and genetic cues affecting 
susceptibility. For example, concordance rate among monozygotic twins is around 
25%, whereas it is approximately 3% for dizygotic twins (12, 13). This discrepancy 
based on genetic sharing shows that inherited genotype is important, but cannot by 
itself explain why some people develop MS. Thus, additionally to providing a genetic 
base for susceptibility, these studies tell us that environmental factors also play an 
important role in determining risk of MS (Figure 2).  
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Figure 2: Life time risk of developing MS is based on relatedness to another person with MS. The closer 
related (higher genetic sharing) a proband and a relative are, the higher that relative’s lifetime MS risk. 
The graph is based on a meta-analysis of familial MS studies by Compston et al (1). 
 
1.1.1.1 Genetics 
 
Many linkage studies looking at family pedigrees with high MS prevalence have tried 
to identify rare mutations capable of causing MS independently of environmental 
influence or conversely, environmental triggers strong enough to cause disease without 
genetic predisposition, but with little luck. Instead the new era of genome wide 
association studies (GWAS) has provided an approach which has been much more 
fruitful. The number of genetic regions that are convincingly associated with disease 
risk has increased dramatically from 1 to more than 50 in the last 6 years (14). 
Interestingly, most of the disease associated genes regulate immune rather than 
neurological functions. This fact underlines the importance of immune pathways in the 
initial break of self-tolerance causing disease onset. Disease progression and severity 
however do not seem to be regulated by the same genetic polymorphisms that 
predispose to acquiring disease. The alleles associated with MS susceptibility have 
shown a lack of impact on MS severity in several studies including Paper II of this 
thesis (15-17). Recent multi-center GWAS looking for markers of disease severity 
paint a complex and heterogeneous picture of genetic influence, with several of the 
strongest candidates being genes regulating neuronal function rather than general 
immunity (18, 19). Together these studies suggest that MS onset is triggered by general 
immune mechanisms, whereas different, organ specific modulators guide disease 
progression. In support of that model, several of the genes associated to MS 
susceptibility have also been associated to other autoimmune disorders e.g. psoriasis 
(IL12B), Crohn’s disease (STAT3), rheumatoid arthritis (IL2RA) and type 1 diabetes 
(IL7R) (14). Given these overlaps between diseases, it seems likely that these 
polymorphisms affect the initial break of self-tolerance (in a disease unspecific manner) 
 4 
through common immunological mechanisms, rather than later events in already 
established disease.  
 
The strongest genetic associations to MS (and indeed most other autoimmune diseases) 
lie in the Human Leukocyte Antigen (HLA) region. Whereas risk alleles of the genes 
found in GWAS have odds ratios of about 1.2, the strongest HLA association 
(HLA*DRB1501) has a reported odds ratio of ~3 (>20 for HLA*DRB1501 
homozygotes lacking HLA*A02 (20)). The HLA association strengthens the case that 
immunological processes including antigen presentation are at the core of determining 
MS risk.  
 
1.1.1.2 Environment 
 
Environmental triggers of MS are less well characterized but known to be important. 
The fact that monozygotic twin concordance (mentioned above) is ~25% and not 100% 
indicates environmental exposures have great influence on disease susceptibility. 
Furthermore, migration studies have shown that people moving from a low-prevalence 
area to a high-prevalence area tend to retain their low MS susceptibility whereas people 
moving the opposite direction i.e. from high to low prevalence areas reduce their risk of 
developing MS (21). This combination of epidemiologic data suggests that 
environmental exposures during childhood and adolescence are of essential importance 
for disease risk. Indeed, the positive effects of migrating from a high risk to a low risk 
area are greatest if the migration happens before the age of 15 (22). There are currently 
three environmental factors that are widely accepted to increase MS susceptibility: low 
vitamin D levels, cigarette smoking and Epstein-Barr virus (EBV) infection. Each is 
discussed below. 
 
1.1.1.2.1 Vitamin D 
 
One quite solid determinant in whether an area has low or high MS risk is latitude. It 
seems that the further an area is from the equator the higher the MS prevalence. This 
fact has pointed to ultraviolet radiation or vitamin-D as likely protective agents against 
MS development (23). Geneticists have tended to point out minorities with low MS 
incidence living near the poles e.g. the Sami of Scandinavia, as proof that the latitude 
gradient has more to do with ethnicity than sun exposure. Since environmental factors 
(such as sun-light exposure) are considerably harder to accurately quantify than genetic 
factors it remains challenging to accurately and completely understand the latitude 
effect. A recent study on American army veterans who served during the first gulf war 
surprisingly pointed to an increased MS incidence amongst African-Americans 
compared to Caucasian Americans (24). This is surprising considering MS rates in 
western Africa, where most African Americans stem from are much lower than in 
Europe, which is the main origin of Caucasian Americans. One clue to explaining this 
difference could lie in skin color. Higher skin pigmentation (i.e. darker skin) has been 
associated with decreased cutaneous synthesis of Vitamin D (25), and African 
American women have lower Vitamin D levels than Caucasian American women (26).  
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A link between Vitamin D insufficiency and several other immune mediated diseases 
has been observed, and is believed to be connected to effects on the adaptive immune 
response (27). 
 
1.1.1.2.2 Epstein - Barr Virus 
 
Infection with EBV has long been suspected of increasing MS risk. EBV infection is 
typically asymptomatic during childhood, but generally leads to infectious 
mononucleosis in adolescents or adults. The chance (or risk) of avoiding childhood 
infection is greatest in countries with high standards of living, hence the 
epidemiological map of infectious mononucleosis (implying a person was not exposed 
to EBV during childhood) correlates well with MS prevalence. Furthermore, the risk of 
several autoimmune diseases (as well as MS) in developed countries has steadily 
increased over the last few decades whereas the risk of infections has declined (28). 
One possible explanation for this phenomena is the so called “hygiene hypothesis” 
which states that a lack of exposure to common pathogens causes an increased risk of 
allergy and autoimmunity. This would explain the link between MS and infectious 
mononucleosis without necessarily providing a direct link between the two. A direct 
link is instead provided by the knowledge that people who remain uninfected with EBV 
throughout life have an extremely low risk of developing MS, whereas infectious 
mononucleosis increases the MS risk 2.3 fold compared to infection during childhood 
(29, 30). 
 
1.1.1.2.3 Cigarette Smoking 
 
There is clear evidence of an association between cigarette smoking and increased MS 
susceptibility (31-34). Swedish snuff, which is high on nicotine does not seem to have 
the same effect (34). It has been suggested that the increased MS risk amongst smokers 
(~50% between ever-smokers and never-smokers) combined with changing gender 
habits (more women smoke cigarettes today than previously) could provide the entire 
explanation as to why the gender gap between female and male MS incidence is 
growing (35). Several plausible explanations to the mechanism linking cigarette smoke 
and MS have been put forward including disruption of the BBB, increased nitric oxide 
production and immunomodulatory effects (35). Further investigation is needed to 
elucidate the exact biology of these intriguing findings. 
 
1.1.2 MS Severity 
 
MS severity is a very important, but not entirely straightforward concept. It is important 
since clinical trials and biological understanding of the disease rely on quantifying the 
level of disability and determine what affects it. Disability is defined by the World 
Health Organization as: “an umbrella term of impairments, activity limitations and 
participation restrictions” (36). The concept of disability is thus centered on a 
person’s ability to interact with its environment, an ability strongly impaired by MS. 
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The most widely used scale for assessing MS disability is the Expanded Disability 
Status Scale (EDSS) outlined by Dr John Kurtzke in 1983 (37). Essentially, an EDSS 
score is determined based on disability in functional systems (pyramidal, cerebellar, 
brainstem, sensory, bowel/bladder, visual and cerebral) at lower scores, and mostly on 
motoric impairment at higher scores. The scale runs between 0 (no neurological 
symptoms) and 10 (death due to MS). The EDSS has received much criticism for 
various shortcomings including bad correlation with MRI lesions (38), poor 
consistency between ratings and raters (39, 40), too much focus on walking capacity 
and too little focus on cognitive impairment (41). Despite all these negative side notes, 
EDSS remains the most widely used disability scale in MS, possibly due to lack of 
competition (in quality not quantity). Furthermore, MS does not have many solid 
endpoints to tie a scale too. Death is a poor endpoint since MS does not have a very 
strong effect on longevity. Relapse-rate has also been proven to correlate weakly with 
overall disability, and is prone to variation between physicians’ definition and calling of 
a relapse.  
 
1.1.3 The Pathophysiology of MS 
 
There is some controversy about whether the primary mechanism of MS is 
inflammatory or neurodegenerative (42). Most of the community remains convinced 
however that immune mediated inflammation plays a central role in pathogenesis credit 
to animal experiments and the efficiency of immune modulatory drugs. The onset of 
inflammation in MS is dependent on auto reactive, myelin specific lymphocytes 
entering the CNS. An obstacle for them to do so is the BBB, which provides the CNS 
with an immunologically protected environment. Previously the BBB was thought to 
disable lymphocyte trafficking into the cerebrospinal fluid (CSF) and the brain, and 
thereby rendering the CNS an immune privileged site. Instead, it seems that activated 
T-cells (the main leukocyte in CSF), by expressing adhesion molecules, integrins 
(including the α4-integrin targeted by the MS therapy natalizumab, discussed in 
chapter 1.1.4.2 (43)) and chemokine receptors, can actively diffuse across the BBB 
(44). In order for this to happen, T-cells specific for myelin antigens need to be 
activated in the periphery, leading to subsequent migration across the BBB. In the CNS, 
antigen-presenting cells (APCs, primarily activated microglia) reactivate the T-cells, 
which in turn induce specific degradation of the myelin sheath. It is unclear how the 
auto reactive, myelin specific T-cells are activated in the periphery, considering there is 
no lymph in the brain. CSF has the ability to drain antigens and immune cells to the 
cervical lymph nodes, and it has been suggested that it can substitute for the lack of a 
lymphatic system in the CNS and thereby present myelin antigens to auto reactive T-
cells (45-47). Epidemiologic studies however have not been able to clearly establish an 
MS protective effect of childhood tonsillectomy (48, 49). Another hypothesis is that 
myelin proteins from damaged peripheral nerves provide the antigen needed for the 
APC triggered initial peripheral activation of T-cells (50). After activation these cells 
could cross the BBB and cause the more organ specific damage. This model works well 
to explain why immunization with peptides from myelin basic protein (MBP, a protein 
present in both central (Oligodendrocyte created) and peripheral (Schwann cell created) 
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myelin) triggers the MS animal model Experimental autoimmune encephalomyelitis 
(EAE) in mice. EAE resembles MS pathogenesis and can have a relapsing-remitting or 
progressive disease course depending on the specific model animal used. Finally, the 
concept of molecular mimicry has also gained much attention as a plausible 
explanation for peripheral activation of T-cells (51). The molecular mimicry hypothesis 
is based on the capacity of pathogen specific T-cell receptors (TCR) to cross-react with 
myelin peptides. For example, strong similarities in a peptide sequence from human 
herpesvirus 6 (HHV-6) and a different peptide from MBP have been shown to be 
similar enough that the HHV-6 peptide could be used to activate MBP specific T-cells 
from MS patients in vitro (52).  
 
The main function of the immune system is to provide self-tolerance while maintaining 
a potent defense against harmful pathogens. This involves selection against auto-
reactivity through maintenance of central tolerance (in the thymus) and peripheral 
tolerance. Both MS patients and healthy subjects have myelin specific naïve T-cells in 
their periphery, which have escaped central tolerance (53). Peripheral tolerance is a 
complex mechanism maintained by anergy, clonal deletion and regulatory T-cells (T-
regs) to prevent an autoimmune response. Thus, for autoimmune events to happen in 
MS, myelin specific T-cells need to both escape central tolerance (which happens to 
everyone) and peripheral tolerance (which triggers the onset of myelin degradation). 
One issue with the break of peripheral tolerance is that presenting a myelin peptide on 
major histocompatibility complex (MHC) to a myelin specific T-cell is not enough. 
When an APC and a naïve T-cell interact, the T-cell will only become an activated 
effector if both signal 1 (antigen presentation on MHC) and signal 2 (co-stimulation, 
primarily by binding between CD28 on the T-cell and CD80/CD86 on the APC) is 
delivered by the APC. For this to happen the APC must itself be active, a process 
relying on binding of pattern-recognition receptors to pathogen (PAMPs) or tissue 
damage (DAMPs) derived antigens (54).   
 
The strong genetic link to HLA class II as well as adoptive transfer experiments with 
myelin reactive T-cells in mice have led to the conclusion that MS is primarily a CD4+ 
(helper T-cell) mediated disease (55). Within the CD4+ family of T-cell subsets, 
initially type 1 T helper (Th1) cells were seen as likely drivers of inflammation. Much 
of the underlying work behind this hypothesis was carried out in the main animal 
model of MS: (EAE). Interleukin-12 is a critical factor for differentiation of naïve T-
cells into Th1 cells and consists of two subunits: p35 and p40 (the complete 
heterodimer is sometimes referred to as IL-12p70). The work identifying Th1 cells as 
central in MS pathogenesis was largely based on studies of EAE in p40-/- mice (56) or 
with antibodies directed against p40 (57-59). However, a few years later another 
cytokine that also carries the p40 subunit, but in this case together with p19 was 
discovered: IL-23 (60).  IL-23 was shown to be the critical cytokine rather than IL-12 
in EAE pathogenesis (61-63), and the effect was shown to be Th1 independent but 
rather relying on a new IL-17 producing helper T-cell lineage (now known as Th17 
cells) (64). IL-23 is essential for the maturation of Th17 cells and this cell subset is now 
receiving much attention for its involvement in EAE and MS. In a recent study, MS 
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patients during relapse were shown to have on average 3-fold higher Th17/Total CD4+ 
ratio in CSF compared to controls with other (non-inflammatory) neurological 
disorders (65). No difference was seen in peripheral blood. 
 
Although Th17 is getting a lot of attention in MS research lately, it should be noted that 
there is considerable plasticity between T helper cell populations (66). For example, 
Th17 cells have been shown to start behaving like Th1s (produce interferon gamma) 
both in vitro (67) and in vivo (68) under inflammatory conditions. This gives some 
vindication to the early efforts identifying Th1 as the target cell subset.  
 
1.1.4 MS Treatments 
 
There are currently six approved disease-modifying compounds used for MS treatment. 
Additionally, autologous hematopoietic stem-cell transplantation after total body 
irradiation as a means of “resetting” the immune system in severe, progressive MS has 
shown promising results. A recent meta-analysis showed that the mean progress-free 
survival 3 years after treatment was 60-70%, impressive considering the clinical history 
of these cohorts (rapidly progressing disease) (69). The effects seem even better in 
RRMS subjects frequently showing improved EDSS scores. However, the treatment 
related mortality risk of approximately 2% is a serious obstacle to expand this treatment 
strategy amongst non-severe MS patients (70, 71).  
 
1.1.4.1 Interferon Beta 
 
IFNβ has been the most widely used therapy for RRMS treatment over the last 20 
years. Although clinical trials have shown a 30% reduction in relapse rate and reduced 
MRI activity (72, 73), the long-term benefits in terms of reduced disability are disputed 
(74, 75). The mechanism behind IFNβ’s clinical effects is not completely understood, 
but several possible explanations have been investigated. One hypothesis is based on 
IFNβ’s immune modulatory properties as a skewer of the cytokine balance towards a 
more anti-inflammatory milieu (76-78). This “cooling” of the immune system may 
benefit MS patients by reducing the inflammation induced tissue damage of the CNS. 
Another hypothesis is based on IFNβ’s ability to strengthen the integrity of the BBB by 
reducing expression of adhesion molecules needed for activated lymphocytes to 
migrate across it (79).  
 
1.1.4.2 Natalizumab 
 
The most effective treatment of RRMS to date is a monoclonal antibody called 
natalizumab. Natalizumab binds the alpha-4 integrin subunit (α4) which is a crucial 
component in the α4β1 and α4β7 integrins utilized by lymphocytes to migrate into 
tissue (including across the BBB into the CNS). The drug has been shown to reduce 
MRI identified lesions in the CNS as well as an overall reduction of disease progression 
(43, 80). One problematic side effect of disabling lymphocyte traffic across the BBB is 
the reduced ability of the immune system to deal with opportunistic infections. 
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Particularly the John Cunningham (JC) virus has been problematic, and led to serious 
side effects in the form of progressive multifocal leukoencephalopathy (PML) in RRMS 
patients on natalizumab treatment. As of May 2012, 212 cases of PML had been reported 
out of almost 100,000 RRMS patients treated with natalizumab (81). This serious side 
effect has led to natalizumab generally being prescribed only in severe MS cases, and after 
evaluation of other risk factors for PML including JC-antibody titers and previous 
administration of immunosuppressant drugs(82).  
 
1.1.4.3 Glatiramer Acetate  
 
Glatiramer acetate consists of a random peptide containing the four most common 
amino acids in MBP, and was originally intended to trigger EAE in mice. Instead it 
turned out to render rhesus monkeys immune to EAE induction (83), leading the 
investigators to research its potential as an MS drug. Its proposed mechanism of action 
is to induce tolerance against myelin antigens through competition with MBP peptides, 
thereby preventing an immune response against the myelin (84). Glatiramer acetate has 
similar long-term treatment efficacy for RRMS as IFNβ according to two recent studies 
(85, 86). 
 
1.1.4.4 Other Treatments 
 
Additionally there are three approved MS therapies prescribed more rarely than IFNβ, 
natalizumab and Glatiramer acetate. Except for Mitoxantrone, these are all used to treat 
RRMS exclusively. 
 
• Fingolimod – The first oral RRMS drug Fingolimod modulates the sphingosine 
1-phosphate receptor, which prevents lymphocytes from exiting lymph nodes. 
As a result, patients have ~50% reduced relapse rate and slowed progression of 
disability (87). Side effects of the induced immune modulation include 
opportunistic infections and skin cancer.  
 
• Mitoxantrone – Used to treat both RRMS and SPMS, Mitoxantrone impairs 
DNA synthesis and repair leading to disabled lymphocyte proliferation. The 
drug is fairly well tolerated, although it should not be given for more than 2 
years in total due to adverse side effects (88). It reduces relapse rate in RRMS 
and slows EDSS increase in both RRMS and SPMS. 
 
• Teriflunomide – The latest approved treatment of RRMS, this oral drug blocks 
the synthesis of pyrimidine, thereby inhibiting DNA synthesis crucial for 
proliferating cells. The methodological reasoning is similar to that of 
Mitoxantrone i.e. inhibition of effector cells targeting myelin to undergo rapid 
proliferation and hence blocking powerful immune responses. Teriflunomide 
has similar effects on relapses and clinical outcomes as IFNβ and Glatiramere 
acetate with the added benefit of oral administration rather than injection (89, 
90).  
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Furthermore, corticosteroids are sometimes given to RRMS patients as immune 
suppressants during a relapse. All the currently approved MS-therapies are in one way 
or another immune modulatory, and are focused on blocking crucial steps in immunity 
mediated myelin destruction (summarized in figure 3). Future challenges include 
developing therapies with organ specific effects such as stimulating re-myelination. 
Ongoing trials using autologous mesenchymal stem-cell transplantation in MS and 
neural stem-cell transplantation in amyotrophic lateral sclerosis could provide a first 
step in that direction (91, 92). 
 
 
 
Figure 3: Schematic view of pathophysiologic targets of the currently approved MS drugs. APC (blue) 
presents a myelin peptide on MHC to an auto-reactive T-cell (red) leading to their activation and 
proliferation (A). These processes are targeted in different ways by the immune modulatory drugs IFNβ, 
Glatiramere acetate, Mitoxantrone and Teriflunomide. The activated T-cell by up-regulating integrins and 
chemokine receptors can then traffic out of the lymph node (inhibited by Fingolimod), into the blood 
stream and across the BBB (inhibited by Natalizumab) into the CNS (B). In the CNS, the T-cell is 
reactivated by local APCs (primarily activated microglia, green (C)) and induces an immune response 
against the myelin sheath (blue) covering a neuron’s (yellow) axon (D).  
 
1.1.4.5 Future Treatments 
 
There are currently a large number of ongoing clinical trials of new therapies in MS. 
Most of these target different components of the immune system. A few of them are 
discussed below. 
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• Alemtuzumab – A monoclonal anti-CD52 antibody that leads to T-and B-cell 
depletion, but does not target hematopoietic stem cells. Alemtuzumab has 
showed great clinical efficiency when RRMS patients were treated early in 
disease (actually decreasing EDSS score 5 years into treatment) (93, 94). 
Relapse-rate and sustained disability is reduced by approximately 70% 
compared to IFNβ treatment. 
 
• Daclizumab – Daclizumab is a monoclonal antibody targeting the IL-2 receptor 
α chain (CD25). CD25 is crucial for the autocrine IL-2 stimulation that T-cells 
utilize to induce proliferation upon antigen recognition. Combined treatment 
with IFNβ led to fewer new or enlarged MRI lesions but did not impact EDSS 
(95).  
 
• Rituximab and Ocrelizumab – Anti-CD20 monoclonal antibodies targeting B-
cells. B-cells are a logical target in MS since they both function as (myelin 
specific) antibody producers and professional APC (i.e. expresses MHC class II 
and hence have the ability to activate CD4+ T-cells). Rituximab and 
Ocrelizumab’s efficacy is disputed, and side effects can be severe. Decreased 
MRI lesions have been reported (96-98), however it does not seem like these 
compounds will be new blockbuster drugs in MS. 
 
• RTL1000 – Is an elegant approach to MS treatment. RTL1000 consists of a 
peptide which forms an MHC+myelin oligodendrocyte protein peptide 
(DR2+MOG35-55) intended to deliver signal 1 in the absence of signal 2 to 
myelin specific T-cells. The intention is to induce peripheral tolerance through 
anergy of these myelin specific T-cell clones (99).  
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1.2 INTERLEUKIN-7  
 
IL-7 was initially identified in as a growth factor for murine B-cell development (100). 
Later, it was established that IL-7 additionally promotes murine T-cell maturation (101) 
and that it exerts similar stimulatory effects on human lymphocytes. There is one big 
difference between IL-7’s role in humans and mice however. The first report showing 
that people carrying IL7R (the gene encoding IL-7 receptor alpha chain (IL7RΑ)) loss 
of function mutations can develop severe combined immunodeficiency (SCID), 
surprisingly found that these patients although lacking T-cells had relatively normal B-
cell numbers in blood (102). IL7-/- and IL7R-/- knockout mice on the other hand have 
severe T- and B-cell lymphopenia (101, 103, 104). Thus, as far as adaptive immunity 
goes, in humans IL-7 is mainly a regulator of T-cell development and survival whereas 
mice additionally need IL-7 to generate B-cells.   
 
Apart from its non-redundant status in the development of adaptive immune cells, IL-7 
has recently been identified as a key cytokine for innate lymphoid cells (ILC). Initially, 
ILCs were thought to exclusively consist of natural killer (NK) cells (105), but it is now 
known that the ILC repertoire encompasses a wide range of cell subsets with different 
immunological functions (including natural helper cells (NH) and lymphoid tissue 
inducer cells). Interestingly, all of these ILC subsets express IL7RΑ, and IL-7 
stimulation is important for their development and survival (106).  
 
1.2.1 IL-7 Production 
 
IL-7, ironically, is not technically an interleukin. The name interleukin implies 
signaling between two leukocytes, and whilst the primary function of IL-7 signaling is 
to stimulate growth and survival of different leukocyte subsets, the main producers of 
this cytokine are stromal cells of the primary and secondary lymphoid organs (107). 
The production of IL-7 is generally considered constitutive i.e. it is produced at a stable 
rate. IL-7 concentration in blood is thus primarily regulated by consumption rather than 
production. Indeed, under lymphopenic conditions (i.e. few IL-7 consuming cells) IL-7 
levels are elevated, and there is an inverse correlation between T-cell numbers and 
serum IL-7 levels (108, 109). The strength of the IL-7 signal on an individual 
lymphocyte is thus regulated by receptor expression rather than cytokine production.   
 
1.2.2 IL-7 in the Thymus 
 
In the thymus, IL-7 has a central role in the maturation of thymocytes to single positive 
T-cells. During this process called thymopoiesis, thymocytes are dependent on IL-7 
stimulation at several stages (110). IL-7 is always present in the thymus since thymic 
stromal cells are its main producers. Signaling is instead tightly controlled by IL7RΑ 
up- and down regulation during the different stages of T-cell maturation. Simply put, 
IL7RΑ expression is absent in early thymic progenitor cells, present on double negative 
thymocytes (CD3+/CD4-/CD8-), down-regulated again during the double positive 
stage (when thymocytes undergo positive selection; CD3+/CD4+/CD8+) and then re-
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expressed on single positive naïve CD4+ and CD8+ T-cells during negative selection 
and when exiting the thymus. Maintained surface IL7RΑ expression is crucial for T-
cell’s survival and for the potential of homeostatic proliferation in the peripheral 
lymphoid organs (111). 
 
1.2.3 IL-7 in the Periphery 
 
After puberty the thymus slowly starts shrinking and eventually loses most of its ability 
to provide the T-cell niche with naïve cells (112). Instead, peripheral maintenance and 
proliferation of T-cells becomes increasingly important. All naïve T-cells have low 
affinity for self-peptides presented on MHC as a result of positive and negative 
selection in the thymus. Survival of naïve T-cells utilizes this axis and is dependent on 
TCR stimulation through self-peptide + MHC complexes as well as anti-apoptotic 
signals delivered by IL-7 (113). Under normal physiological conditions, these signals 
primarily induce survival and cycling of peripheral T-cells, and the strength of the 
combined stimulation (self-peptide + MHC and IL-7) is not enough to induce activation 
and proliferation but mainly serves to prevent apoptosis. Under lymphopenic conditions 
however, homeostatic proliferation in the periphery occurs. This lymphopenia induced 
expansion of naïve and memory T-cells can be initiated by disease (e.g. HIV) or as a 
result of therapy (e.g. chemotherapy against various tumors). As IL-7 consumption is 
reduced, serum IL-7 levels rise and reach a threshold where cells start dividing. This 
homeostatic proliferation is less tightly controlled than thymic expansion, and is 
believed to be a contributing factor to the link between lymphopenia and autoimmunity 
(114). Memory T-cell homeostasis is also dependent on IL-7 signal, however they do 
not need TCR stimulation by self-peptide + MHC complexes to the same extent as 
naïve cells do (115).  
 
There is mounting evidence that T-regs are less dependent on IL-7 stimulation than 
other T-cell subgroups. Firstly, IL7RΑ expression is low or absent on T-regs, and its 
expression inversely correlates with the expression of the forkead box P3 protein 
(FoxP3, a T-reg marker) and T-reg’s suppressive capacity (116).  In the periphery, T-
regs are not dependent on IL-7 for survival or homeostatic proliferation (117). 
However, thymopoiesis seems to be IL-7 dependent also in the context of T-reg 
production (118). Together, this data suggests that although IL-7 signaling is non-
redundant for all thymopoiesis, in the periphery, activation and survival signals 
mediated by IL-7 favor non T-reg subsets. Indeed, clinical trials with recombinant 
human IL-7 (rhIL7) have shown preferential expansion of non T-regs resulting in a 
diminished relative frequency of regulatory T-cells (119, 120). In contrast, recombinant 
human IL-2 therapy skews the T-cell repertoire in favor of T-regs (121). 
 
1.2.4 The IL-7 Receptor 
 
The IL-7 receptor is a heterodimer consisting of the IL7RΑ chain and the common 
gamma chain (γc or CD132). Both these chains form other cytokine receptors when 
complexing with different chains (figure 4). The sister cytokine of IL-7, Thymic 
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stromal lymphopoietin (TSLP) which utilizes IL7RΑ for signaling, can to some degree 
substitute for IL-7 signaling. This is thought to be the reason why IL7-/- mice are less T-
cell lymphopenic than IL7R-/- mice (122). Shortly after the successful identification of 
IL-7 (100), the IL-7 receptor was cloned and characterized by Goodwin et al (123). 
Quite soon, IL7RΑ by itself was shown to have intermediate affinity for IL-7 
(dissociation constant in the micro molar (μM) range) whereas the complex of IL7RΑ 
and CD132 binds IL-7 stronger (dissociation constant in the pico molar (pM) range; 
(124)). IL7RΑ expression is tightly regulated both during T-cell development and in 
mature T-cells. As discussed earlier (Section 1.2.1), IL-7 production is stable and hence 
the main tool for controlling signal strength is through regulation of IL7RΑ expression. 
This is actively carried out for example upon IL-7 stimulation when IL7RΑ is down-
regulated. By regulating IL7RΑ expression, IL-7 is preserved for other cells in an 
altruistic fashion, which ensures that a limited resource (IL-7) is not excessively 
consumed (110, 125).  
 
 
 
Figure 4: Both chains of the IL-7 receptor can form other cytokine receptors when bound to alternative 
receptor chains. IL7RΑ forms the TSLP receptor in complex with the TSLPR chain (left). CD132 can 
form six different cytokine receptors based on which additional receptor chain it complexes with (right). 
 
 
1.2.5 IL-7 in Autoimmunity 
 
Counter-intuitively, there is a well-established link between lymphopenia and 
autoimmunity (126-128). IL-7 is likely important in this chain of events due to the fact 
that its concentration in plasma inversely correlates with lymphocyte counts and IL-7 
signaling induces homeostatic proliferation at high concentrations (114, 129). 
Furthermore, IL-7 has been shown to be a co-factor in the development of 
autoimmunity based on studies in animal models. IL-7 transgenic mice develop an 
autoimmune dermatitis phenotype, and administering IL-7 worsens mouse models of 
MS and ulcerative colitis, whereas blocking of IL7RΑ mitigates disease (130-132).  
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Further evidence of IL-7’s involvement in autoimmune disease comes from the large 
number of autoimmune diseases genetically associated to polymorphisms in the IL7R 
gene (which encodes for IL7RΑ). The alleles associated with increased risks of MS 
(133, 134), ulcerative colitis (135), sarcoidosis (136) and primary biliary cirrhosis (137) 
are in strong linkage disequilibrium, and hence usually co-inherited. This fact suggests 
that these diseases share a common biological explanation to the genotype-
autoimmunity link. Evidence put forward by others (134, 138, 139) as well as in paper 
III of this thesis support an involvement of soluble IL7RΑ. Additionally MS has been 
genetically associated with the IL-7 encoding gene IL7 (14). This finding is relatively 
new and the mechanism behind is yet to be investigated, but it does provide the first 
cytokine + receptor pair convincingly associated to MS susceptibility. 
 
1.3 SOLUBLE RECEPTORS 
 
The biology of soluble receptors is a nascent field in immunology. Conservation across 
species and their abundance in serum indicates that these proteins have important 
biological functions (140). Soluble cytokine receptor’s functions vary from reducing 
signaling strength (e.g. soluble IL1RII (141)) to greatly enhancing bioactivity of the 
target cytokine (e.g. soluble IL15Rα (142, 143)). Some soluble receptors have shown 
various abilities under different conditions. Soluble IL2Rα, has been reported to both 
potentiate (144, 145) and diminish (146) IL-2 signaling on T-cells. Similarly, a 
previous report on soluble IL7RΑ chain (sIL7RΑ) has shown IL-7 inhibition in the 
presence of an IL-7Rα-Fc fusion protein constructed to mimic sIL7RΑ (147). Our data, 
on the other hand show a preserving and potentiating effect of sIL7RΑ on IL-7 
signaling in various experimental systems (paper III).  
 
There are two methods utilized by cells in order to produce soluble receptor isoforms: 
membrane shedding and alternative spicing (140). Membrane shedding is based on 
proteolytic cleavage of the extracellular domain of membrane bound receptors (e.g. 
TNF receptor 2 (148)), whereas alternative splicing of mRNA (messenger ribonucleic 
acid; e.g. IL-9 receptor alpha chain (149)) leads to receptor secretion. Typically this is 
due to the alternative splicing generating a different mRNA molecule, which is then 
translated into a protein isoform lacking the membrane-anchoring domain (figure 5). 
Soluble IL7Rα is primarily generated through this alternative splicing based 
mechanism (150). It is present at high molar excess compared to IL-7 (>1000-fold, 
paper III), and its abundance is highly dependent on IL7R genotype. 
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Figure 5: Generation of soluble cytokine receptors. (a) Intron splicing generates an mRNA molecule 
containing all exons (in this example exon 1-7). Translation renders a full-length protein containing intra-
cellular, trans-membrane and extra-cellular domains. (b) The extra-cellular portion of the full-length 
receptor is shed, generating a soluble isoform identical to the extra-cellular domain of the membrane 
anchored isoform. (c) The second option occurs when alternative splicing results in the production of an 
mRNA isoform lacking the exon encoding the trans-membrane domain (in this example exon 4). (d) Due 
to excision of exon 4, translation of this mRNA leads to production of a protein lacking membrane-
anchoring capability. An altered reading frame (the nucleotide bases in exon 4 were not evenly dividable 
by 3: the size of an amino acid coding codon) results in translation of a unique peptide downstream of the 
extra cellular domain (blue striped).  
 
The effects of soluble receptors on our immune system are as diverse as the effects of 
the cytokines they bind. Many have shown to have strong influence on disease and 
health. For example, the auto inflammatory Tumor necrosis factor (TNF) receptor 
associated periodic syndrome (TRAPS), can be caused by inability to shed TNF 
receptor 1 (151). High soluble IL2Rα levels are correlated with worse outcome in 
Hodgkin’s disease (152) and sIL7Rα is increased in HIV patients (147, 150). The 
future will hopefully bring greater understanding, and therapeutic approaches involving 
these mediators of cell-based signaling. 
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2 AIMS OF THESIS 
 
The aim of this thesis was to determine how genetic risk factors, particularly the IL7R 
association, influence MS pathology. Specifically the core aims of each project are 
listed below. 
 
Paper I: The genetic associations to MS susceptibility prior to this study where in genes 
regulating T-cell response and without clear organ specificity. This paper investigates a 
gene with documented importance for CNS function: KIF1B, which encodes the 
kinesin family member 1B protein.  
 
Paper II: Several genetic associations to MS susceptibility had been made prior to this 
paper. Our aim was to evaluate whether polymorphisms associated with MS risk also 
impacted MS severity. An alternative hypothesis going in to this project was that some 
MS susceptibility markers were actually affecting severity and thus leading to quicker 
and more accurate diagnosis. 
 
Paper III: The first non-HLA gene associated with MS susceptibility was the IL7R 
gene, which encodes the IL7RΑ chain. This paper elucidates the functional 
implications of IL7R genotype, and how it influences MS susceptibility. Specific 
attention was given to the biology of soluble IL7RΑ. 
 
Paper IV: IFNβ is the most widely used first-line treatment in RRMS, and is known to 
have strong immune modulatory properties. We investigated how IFNβ administration 
impacts IL-7 biology. 
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3 MATERIALS AND METHODS 
 
For detailed descriptions of methodology, see the individual methods section of that 
constituent paper. A brief overview of the methods used most follow in this chapter. 
 
3.1 HUMAN SAMPLES 
 
All patient and control materials used by me in these studies were collected after 
informed consent had been given by the individual donor. Ethical approvals were 
obtained from the regional ethical review board in Stockholm County. The protocols 
for enrollment of subjects were designed to cover several projects outside of this thesis, 
and thus are not specifically formulated for these experiments. Patients and controls 
were either enrolled in the EIMS (environmental factors in multiple sclerosis) or 
StopMS (Stockholm prospective assessment study of multiple sclerosis) projects.  
 
3.2 IN VITRO EXPERIMENTS 
 
3.2.1 Genotyping 
 
All genotyping was performed by allelic discrimination on a Taqman platform (Applied 
Biosystems). The allele specific primers and probes (Assay ID for rs6897932 (paper 
III): C_2025977_10 and for rs10492972 (paper I): C_30400488_20) were ordered 
from Applied Biosystems.   
 
3.2.2 Quantitative real-time PCR (qPCR) 
 
Reverse transcription of complete mRNA was carried out with either random hexamers 
or oligo-dT primers. qPCR experiment setups differed between the different studies. In 
paper III, sIL7Ra and IL7Ra were quantified by comparison to plasmid standards of the 
relevant cDNA products with known concentration. GAPDH was used as house-
keeping gene. In paper IV, relative quantity was determined between the product of 
interest and the house keeping gene HPRT1, without the use of a plasmid standard. 
Taqman quantification was carried out by primer+probe pairs ordered from applied 
biosystems (full-length IL7Ra: Hs00904814_m1, sIL7Ra: Hs00902337_m1, HPRT1: 
Hs01003267_m1 and GAPDH: Hs02758991_g1). 
 
3.2.3 Enzyme linked immunosorbent assay (ELISA)  
 
ELISAs were used for quantification of human IL-7 and sIL7Rα in serum and plasma. 
For IL-7 quantification a commercially available high-sensitivity kit was used (human 
IL-7 quantikine ELISA kit, R&D systems). sIL7Rα was quantified by a previously 
validated  ELISA (153) using anti-sIL7Ra antibodies from R&D systems. 
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3.2.4 Cell culture 
 
Cell cultures of PBMC were carried out in either serum-free (Aim-V, Life 
technologies) or complete (RPMI1640, Sigma-Aldrich supplemented with 10% heat 
inactivated fetal calf serum, penicillin, streptomycin and glutamate) media. Cell lines 
were cultured in Aim-V with supplemented IL-7 and split every two days. The 
rationale for using minimal media (serum free) for IL-7 studies was to ensure that 
bovine proteins did not interfere with cell signaling. 
  
3.2.5 Flow cytometry  
 
Flow cytometry experiments were done on a FACS Fortessa (BD biosciences) or a 
CyAn Dako (Beckman Coulter) machine. All cells were kept in cold PBS 
supplemented with 0.5% FCS and 0.1% NaN3 during antibody staining and cell sorting. 
Intracellular staining was preceded by cell fixation and membrane permeabilization 
using BD Phosflow fix and perm buffers. 
 
3.3 EAE 
 
EAE is the most widely used animal model of MS, and has been an important tool for 
studying the biology and treatment of MS. Most approved MS therapies have been 
tested for treatment efficiency in rodent and primate EAE models (154). Although the 
clinical and histopathological symptoms of different EAE models correspond well with 
MS (there are relapsing remitting, monophasic and progressive EAE models), the 
triggering of disease differs (155). The most commonly used form of EAE (active-
EAE) is induced by immunization with myelin peptides in complete freund’s adjuvant 
(the method used in paper III of this thesis) (156). Alternatively myelin reactive T-cells 
can be adoptively transferred from an actively immunized mouse to induce ”passive 
EAE” in a recipient animal (157). Hence, EAE results from auto-reactivity against a 
single antigen and is triggered by co-injection of an adjuvant, activating the innate 
immune system. MS on the other hand does not have a single antigen explaining its 
pathogenesis, and is not induced by administering adjuvant (154).  
 
Our EAE experiments were based on immunization of C57BL/6 mice with MOG35-55 
peptide and subsequent daily blinded scoring of disease symptoms. The EAE severity 
was determined as follows. 
 
0. Normal  
1. Flaccid tail, no paraparesis  
2. Hind limb weakness evidenced by inability to right itself when placed on the 
back, or inability to grasp with its hindlimbs  
3. Partial hind limb paralysis evidenced by inability to move one hind limb (e.g. to 
withdraw one limb when pinched, but able to bear weight on one limb  
4. Complete hind limb paralysis evidenced by inability to move or withdraw hind 
limbs  
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5. Quadriplegia evidenced by inability to move front and hind limbs 
6. Moribund or dead 
 
Mice with an EAE score of 5 were sacrificed (humane endpoint).  
 
The EAE model we used was monophasic i.e. animals developed a single MS bout. It 
would be interesting to see if a relapsing-remitting EAE model would have given 
different results. 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I 
 
4.1.1 Our findings 
 
We found an association between the rare C-allele of SNP rs10492972 and increased 
risk of developing MS (paper I (158)). The association was first seen in a small, inbred 
Dutch cohort, and later replicated in larger, outbred Dutch, Swedish and Canadian case-
control materials. Rs10492972 is located in an intron of the KIF1B gene, which 
encodes the kinesin family member 1B (KIF1B). KIF1B is a member of the kinesin 
super-family of proteins which are all involved in axonal transport. Specifically, KIF1B 
is a “microtubule motor” which transports synaptic vesicle precursors from a neuron’s 
cell body, through the axon to the synapse (159). Mutations in KIF1B can lead to the 
development of the peripherally demyelinating charcot-marie-tooth disease and KIF1B-
/- mice die at birth of apnea due to impaired neuronal signaling (160). The finding that 
this gene impacted MS susceptibility was the first organ specific genetic association to 
MS-risk. 
 
4.1.2 Other studies 
 
Follow up studies of this study (158) have not seen the same association between MS 
and rs10492972*C (161-163). The difference in results is puzzling to say the least. 
Especially the results from a multi-center study by Booth et al (161), which included a 
different Swedish case-control material than the one used in our study, but did not pick 
up the same signal suggests the initial finding was a false positive. This is remarkable 
for several reasons, and needs to be explained further. Some possible explanations are 
listed below. 
 
1. Our study generated a false positive due to genotyping errors. This hypothesis is 
not very likely considering the genotyping was carried out at three different 
locations. 
 
2. Our study picked up a genotype effect unique to the cohorts studied. This would 
have been a likely discrepancy between ours and other studies if our patient 
and/or control cohorts were particularly homogenous. In such a case, a gene-
gene or gene-environment interaction might have been unique to our study 
population. However, this also seems unlikely regarding the fact that our patient 
cohort came from three different countries.  
 
3. The control groups differed. Perhaps differing criteria were used in picking 
control subjects.  
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4. The patient groups differed. An interesting side-note in a recent Russian study 
was that rs10492972*C was associated with increased RRMS risk but not 
PPMS risk (162), and a study on only PPMS came out negative (163). 
Differences in MS sub-phenotype ratios could provide a plausible explanation, 
especially since these ratios usually vary between different study centers. 
Further support for this hypothesis comes from the fact that the Australian case-
control material, which gives the lowest odds ratio for rs10492972*C in the 
follow up study (Figure 6) was enriched for PPMS (ANZgene cohort in (164); 
>25% PPMS versus ~10% PPMS in general MS population). 
 
5. We made a chance finding. P-values are calculated based on numerous 
assumptions about the investigated cohorts, and reflect an estimated risk of a 
positive finding being a false positive. Although the p-values in both these 
studies look impressive, there is a risk they are somewhat deflated, and hence 
there is still a non-negligible risk that our finding simply was a false positive by 
chance. 
 
6. Since the genotyping in our study happened in three different places, I only 
have complete insight into the Swedish cohort’s experiments and results. 
Perhaps something went wrong in the interpretation or generation of the other 
groups’ data. 
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Figure 6: Odds ratios for the association between rs10492972*C carrier-ship and MS susceptibility. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Genetics (161), copyright 2010. 
 
It is important to clarify why the different studies on rs10492972 have yielded so 
different results. Two of the reports were multi-center studies using stringent statistical 
analysis and yet they reach completely different conclusions (158, 161). Both these 
studies included Swedish cohorts of patients and controls. Surprisingly, whereas the 
Swedish cohort used for paper I showed a statistically significant rs10492972 impact on 
MS risk, the cohort used in the follow-up study did not. It would be interesting to see if 
the odds ratios are similar in these materials regardless of MS sub-phenotype, 
particularly RRMS vs PPMS. 
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4.2 PAPER II 
 
A genetic association to MS susceptibility could just as well be a modulator of clinical 
characteristics causing earlier diagnosis. For example, if a patient group and a control 
group are age matched, a genetic predisposition leading to an earlier age at disease 
onset would be indistinguishable from a susceptibility factor. Likewise, genes 
influencing the speed of disease progression could lead to a clearer phenotype, and 
hence quicker diagnosis. In this study we evaluated the impact of 5 SNPs (Table 1) 
known to impact MS susceptibility on clinical parameters. The objective of this project 
was to elucidate if any of these were surrogate markers for increased disease severity or 
earlier age at onset. Our patient cohort consisted of Swedish and Norwegian MS 
patients of Scandinavian origin. 
  
We evaluated how these 5 genotypes influenced age 
at onset, MS severity score and time to an EDSS 
score of 6. None of the SNP alleles influenced these 
clinical parameters. Furthermore, we separated MS 
patients based on the number of these risk alleles they 
carried. No clinical difference based on number of 
genetic predispositions was seen. Other groups have 
also reported this phenomenon: susceptibility linked 
alleles not influencing disease severity (16, 17, 165). 
Whether effects exist, that are not detected with 
current methodology will have to be explored further.  
 
We were disappointed at first that we did not discover any significant associations 
between these markers and clinical parameters. However, negative data, when gathered 
from such a large patient material as this one (1776 patients) can be highly relevant for 
increased understanding of disease mechanisms. As discussed previously (Section 
1.1.1.1) it seems with our current knowledge as though the risk of MS onset and the 
clinical course of MS are dictated by different mechanisms. The results from paper II 
support this model. In terms of our further ambitions of dissecting the mechanistic 
explanation for the IL7R association (paper III), it was important to confirm that 
IL7R*C actually worsens MS risk rather than MS course, at least according to the 
outcome measures we looked at here. 
 
 
  
Gene SNP 
IL7R Rs6897932 
IL2RA Rs2104286 
CLEC16A Rs3184504 
CD226 Rs763361 
SH2B3 Rs3184504 
Table 1: The SNPs included in paper 
II and their genetic context 
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Figure 8: sIL7Rα binds IL-7 (left panel) but not TSLP (right 
panel). Sensograms illustrate binding curves determined by SPR.
4.3 PAPER III 
 
In 2007, the IL7Rα encoding gene IL7R was confirmed as the first new gene associated 
to MS susceptibility in over 30 years (133, 134, 166). It was the first non-HLA and last 
pre-GWAS genetic association found. The effect is attributable to a functional SNP 
(rs6897932) in the region encoding exon 6 of IL7RΑ. Exon 6 is the trans-membrane 
domain of IL7RΑ, and several reports including paper III of this thesis have linked 
IL7R genotype to the degree of exon 6 inclusion in the transcribed protein (134, 167, 
168). The MS predisposing genotype (Carrying a cytosine at rs6897932, hereafter 
referred to as IL7R*C) is associated with increased skipping of exon 6, resulting in 
higher production of a soluble IL7RΑ isoform (sIL7RΑ; Figure 7b). The rationale for 
this study was to determine how the IL7R*C (and indirectly sIL7RΑ) contributed to 
increased MS risk.  
 
Figure 7: Alternative splicing of IL7Rα. Full-length mRNA is translated into the full-length protein 
containing a ligand binding (LB), trans-membrane (TM) and an intra-cellular domain (IC; a).  Splicing 
out exon 6 generates an mRNA molecule with a shifted reading-frame downstream of exon 6 and a 
premature stop-codon. Translation produces a soluble IL7Rα isoform lacking TM and IC domains, but 
carrying a unique 26 amino acid peptide tail at its C-terminus end (b). 
 
4.3.1 sIL7RΑ binds IL-7 but not TSLP 
 
We used a human embryonic kidney cell-line (HEK293E) to produce sIL7Rα. It 
displayed intermediate binding affinity to IL-7 (nanomolar (nM) dissociation constant 
(Kd)), but in contrast no affinity for the other known IL7Rα signaling cytokine TSLP as 
measured by surface 
plasmon resonance (SPR; 
Figure 8).  This indicates 
that sIL7Rα probably 
only affects IL-7 
signaling, which led us to 
focus on its impact on IL-
7 rather than TSLP 
function. In parallel we 
expressed the extra-
cellular portion of IL7Rα 
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to mimic the membrane bound isoform or a shed version of it. To our surprise we 
measured weaker IL-7 affinity for the IL7Rα extra cellular domain (Kd = 98 nM) than 
for the sIL7Rα (Kd = 6.3 nM). Whether this is due to structural changes of the binding 
site of sIL7Rα due to its unique 26 amino acid tail or not remains to be shown.  
 
4.3.2 sIL7Rα potentiates IL-7 bioactivity 
 
The connection between increased levels of sIL7Rα and increased MS risk, together 
with our findings that sIL7Rα binds IL-7 but not TSLP, rendered us with two 
possibilities:  
 
1. IL7R*C genotype → higher sIL7RΑ levels → diminished IL-7 
signaling; hence IL-7 signaling prevents MS development; or 
2. IL7R*C genotype → higher sIL7RΑ levels → potentiated IL-7 
signaling; hence IL-7 signaling can trigger MS development. 
 
To test whether hypothesis 1 or 2 was the relevant one, we compared IL-7 consumption 
and signaling on a murine IL-7 dependent cell-line (2E8), human peripheral blood 
mononuclear cells (PBMC) and in IL7-/- mice. In all three experimental systems, co-
injection of sIL7Rα + IL-7 led to reduced IL-7 consumption indicating competition 
between sIL7Rα and membrane bound IL7Rα. Furthermore, IL-7 induced survival of 
2E8 cells and homeostatic proliferation of donated T-cells from a congenic strain in 
IL7-/- mice was increased suggesting potentiated IL-7 effect. We also found that EAE 
symptoms were worsened in 
C57/BL6 mice that received 
sIL7Rα+IL-7 compared to mice 
injected with IL-7 alone or PBS 
(Figure 9).  
 
Apart from the quantitative 
differences, sIL7Rα also modulated 
the quality of the IL-7 signal in 
PBMC. Despite initial reduction in 
T-cell activation, over time sIL7Rα 
+ IL-7 injection gave a more 
prolonged and potent stimulation 
than IL-7 alone. The IL-7 induced 
up regulation of the regulatory 
suppressor of cytokine signaling 1 (SOCS1) and CD95 molecules was (partially) 
inhibited in the presence of sIL7Rα. The overall picture from these experiments is that 
hypothesis 2 was accurate, and sIL7Rα provides an IL-7 depot that secures IL-7 
availability over time and counters regulatory mechanisms induced by IL-7 alone. This 
model fits well with our current understanding of IL-7 as an immune stimulatory 
cytokine (169). 
 
Figure 9: Injecting IL-7+sIL7Rα worsens EAE 
symptoms in mice compared to IL-7 alone or PBS 
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4.3.3 IL7R genotype influences sIL7RΑ and IL-7 levels 
 
As expected, we saw increased expression (mRNA) and protein levels of sIL7Rα 
associate with IL7R*C genotype (Figure 10). The effect on plasma IL7Rα was gene 
dose dependent in both MS patients and healthy controls. The genotype effect was of 
similar size for mRNA and protein, indicating that alternative splicing is the main 
production method of sIL7Rα, as had been suggested before (150). We did not measure 
any sIL7Rα in CSF, either due to limitations in the detection level of our assay 
(ELISA), or because sIL7Rα is simply not crossing the BBB. Interestingly, we 
measured approximately twice as high plasma IL-7 levels in IL7R*CC MS patients 
compared to IL7R*TT MS patients or healthy controls (figure 11).  
 
 
 
  
Figure 11: Plasma IL-7 levels vary with IL7R genotype in MS patients but not healthy controls 
Figure 10: Plasma sIL7Rα concentration is determined by IL7R genotype in an allele-dose manner. 
The effect was seen in both MS patients and healthy controls. 
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Why MS patients but not healthy controls carrying IL7R*CC have increased plasma IL-
7 is not clear. Either, there is an unknown genetic or environmental factor that together 
with an IL7R*CC genotype increases systemic IL-7 in some individuals which then go 
on to develop MS. Conversely, MS itself might impact IL-7 levels by fluctuations in 
lymphocyte counts. Perhaps only patients with high enough sIL7Rα have the capacity 
to store excessive IL-7 in a sIL7Rα depot and hence maintain elevated plasma IL-7. It 
would be interesting to look for this genotype effect in patients with other diseases, as a 
first step towards understanding the difference based on MS biology.  
 
 
4.3.4 Discussion 
 
The IL7R*C allele, responsible for increased soluble receptor levels and increased MS 
risk is, surprisingly, much more common than the MS protective allele (IL7R*T; Figure 
12). Several other autoimmune diseases are indirectly linked to IL7R*C (discussed in 
Section 2.1.5 of this thesis and (109)) which makes it even more surprising that there is 
evolutionary pressure towards it. A possible explanation could be that sIL7Rα actually 
helps the immune system to function properly. Since IL-7 is a limited resource in vivo 
(125), the depot provided by sIL7Rα may help to prevent excessive consumption, 
thereby maximizing the immune stimulatory potential of IL-7. Another example of 
such a mechanism of IL-7 preservation is the altruistic down-regulation of a cell’s 
membrane IL7Rα in response to IL-7 signaling (110). These tools of limiting excessive 
IL-7 consumption may be of great importance, since the production of IL-7 is stable 
and not thought to be actively regulated.  
 
The bottom-line may be that the IL7R*C allele increases the immune system’s capacity 
to deal with infections by supplying high levels of sIL7Rα. This may come at the cost 
of a slight increase in various autoimmune diseases, but not to an extent threatening 
reproductive capacity. Inability to effectively fight infections on the other hand can be 
detrimental to survival in a much more direct way than post-adolescence onset of 
autoimmunity. Particularly in developing countries where limited access to medical 
facilities and poor hygienic standards are common, infectious diseases pose a great risk, 
especially in children and young adults (170). These circumstances may be the 
underlying factors why the most beneficial (IL7R*TT) genotype from an MS 
perspective is virtually absent in African populations (Figure 12).  
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Figure 12: Homozygosity for the MS protective allele (IL7R*TT) is rare across different ethnical 
ancestries. Public data obtained from phase 3 of the HapMap project (171). 
 
It remains to be seen what the impact of these findings will be on the MS field. 
Targeting the IL-7 axis could certainly have its advantages, considering it would 
primarily impact non-T-regs. The increased understanding of sIL7Rα may additionally 
be relevant in other disease settings. RhIL-7 is currently being evaluated in numerous 
clinical trials, and perhaps its efficacy could be connected to sIL7Rα levels. A first step 
would be to genotype patients in these clinical trials for rs6897932, since there is such 
strong genetic correlation with endogenous sIL7Rα levels. Perhaps treatment efficacy 
can be improved, and negative regulation avoided with lower dose IL-7 + sIL7Rα 
compared to high dose IL-7 alone. Indeed, the most recently published results from a 
clinical trial of rhIL-7 as a supportive agent of immune reconstitution in bone-marrow 
transplant showed best results with intermediate levels (172). The highest dose gave 
less effective immune reconstitution suggesting regulatory mechanisms and excessive 
consumption may induce negative feedback mechanisms. 
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4.4 PAPER IV 
 
4.4.1 IFNβ treatment leads to elevated serum IL-7  
 
The initial objective of this study was to follow up and clarify the finding (173), and 
later dismissal (174) that high serum IL-7 levels before the start of IFNβ treatment 
predict good treatment response. We did not have the patient material to completely 
investigate a possible correlation 
between serum IL-7 and treatment 
outcome, however, we did notice 
elevated serum IL-7 across the board 
amongst IFNβ treated patients. Patients 
treated with natalizumab did not have 
increased IL-7 levels, suggesting the 
effect was not due to MS pathogenesis, 
but rather to IFNβ itself (Figure 13). 
Furthermore, switching treatment from 
IFNβ to natalizumab led to decreased 
serum IL-7 concentrations in the 
individual MS patients. The type of 
IFNβ compound injected did not 
influence IL-7 levels, but presence of 
neutralizing anti-drug antibodies 
(NAbs) did.  
 
Since IL-7 is constitutively expressed, 
we hypothesized that the increased IL-7 
levels were a product of decreased IL-7 
consumption rather than increased IL-7 production. We focused on two parameters of 
critical importance for IL-7 consumption. 
 
a) The number of IL-7 consuming cells in peripheral blood. 
b) The rate of IL-7 consumption of individual cells. 
 
4.4.2 IFNβ treatment leads to reduced IL-7 consumption  
 
Addressing point a, we compared complete leukocyte, lymphocyte and monocyte 
counts in untreated, IFNβ treated and natalizumab treated MS patients. We saw a 
significant reduction in leukocyte and lymphocyte counts amongst IFNβ treated 
compared to untreated or natalizumab treated patients. The IFNβ effect was strongest in 
patients without NAbs. Natalizumab treatment on the other hand led to significantly 
increased leukocyte, lymphocyte and monocyte concentrations compared to untreated 
or IFNβ treated patients. This data suggests that IFNβ treatment, by inducing a mild 
Figure 13: Serum IL-7 levels of healthy controls 
(HC) and MS patients on different treatments.  
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form of leuko- and lymphopenia, reduces the number of IL-7 consuming cells in 
circulation. 
 
  
 
Figure 14: Peripheral blood leukocyte (a), lymphocyte (b) and monocyte (c) concentrations in MS 
patients. IFNβ treated patients are grouped by NAb status. 
 
Although decreased IL-7 consumption due to reduced cell numbers could be the entire 
explanation, we wanted to look at IL7Rα expression in response to IFNβ to further 
elucidate the mechanism responsible for IL-7 elevation. In vitro we saw reduced 
surface expression of IL7Rα on T-cells and monocytes, as well as reduced IL-7 
consumption in the presence of IFNβ. Furthermore, treatment naïve MS patients had 
significantly higher IL7Rα mRNA expression in CD3+ sorted cells before the start of 
treatment than ≥3 weeks after the first IFNβ injection. Plasma IL-7 was significantly 
increased at this time point, strengthening our in vitro observations of reduced IL-7 
consumption in the presence of IFNβ.  
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4.4.3 Discussion 
 
The results of these experiments present a “hen-or-the-egg problem”: Does IFNβ 
signaling reduce IL7Rα expression, which drives up IL-7 levels? Or does IFNβ 
primarily reduce lymphocyte counts by other mechanisms leading to higher IL-7 levels 
due to reduced numbers of consuming cells, more IL-7 signaling on T-cells and hence 
IL7Rα down-regulation? Either way, increases in IL-7 are a potentially serious side-
effect of IFNβ treatment. 
 
This study, for the first time establishes a direct link between two of the currently most 
relevant and researched proteins in MS pathogenesis: IL-7 and IFNβ. This link between 
the only cytokine + receptor (IL7 and IL7R) pair genetically associated with MS risk 
and the most widely used RRMS therapy lays the foundation for future research into 
the exact mechanisms involved as well as possible treatment modifications. Most 
researchers in the field of MS would agree, systemically elevated IL-7 levels are 
probably not beneficial for the disease modifying capabilities of IFNβ. Apart from the 
obvious involvement of IL-7 in various autoimmune processes, a recent report 
established that IL-7 induces up regulation of the α4 integrin utilized by T-cells to cross 
the BBB (175). Perhaps IFNβ treatment efficacy can be improved if IL-7 is targeted 
simultaneously. 
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5 SUMMARY OF FINDINGS  
 
• KIF1B genotype may influence MS susceptibility 
• IL7R, IL2RA, SH2B3, CLEC16A and CD226 genotypes do not influence 
clinical course despite being associated with MS risk 
• sIL7Rα binds IL-7 but not TSLP 
• sIL7Rα potentiates IL-7 bioactivity in vitro and in vivo 
• IL-7 but not sIL7Rα is present at low dose in the CSF 
• Plasma IL-7 concentration depends on IL7R genotype in MS patients 
• IFNβ leads to increased serum IL-7 levels by reducing consumption 
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6 CONCLUDING REMARKS 
 
In the first years of this century, one of the (if not the) most ambitious scientific 
endeavor in history was finalized: the human genome project (176, 177). At that time, 
very few genetic associations with complex diseases were known, whereas today we 
know of over 1100 loci affecting more than 165 diseases and traits (178). The vast 
majority of these discoveries have happened over the last 5 years with the introduction 
of GWAS. MS genetics has covered a lot of ground since the start of the GWAS era 
going from 2 to more than 50 genetic loci associated to disease risk (179). A similar 
trend has been seen in several genetically complex diseases. Despite all this progress in 
understanding the genetics of disease, the clinical benefits for patients with MS as well 
as other complex diseases have been few to none. In a review article celebrating 10 
years with the human genome, the current director of the National Human Genome 
Research Institute Dr. Eric Green speculates that the lack of clinical progress so far may 
not be entirely surprising (180). The authors reason, there is a lot of biological 
knowledge of disease processes left to acquire before we can really make the push into 
the clinics (Figure 15).  
 
 
 
Figure 15: Schematic hypothetical heat map of individual discoveries (blue dots) in the path from genetic 
discoveries towards improved clinical care. Reprinted by permission from Macmillan Publishers Ltd: 
[Nature] (180), copyright (2011). 
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In MS, there is uncertainty about how much of the disease risk is determined by genetic 
versus environmental factors. Based on epidemiologic studies, the genetic contribution, 
termed heritability, is estimated to constitute 25-75% of the disease risk (181). The 
genetic associations to susceptibility determined so far do not add up to explain the 
entire hereditary portion of the disease. This is sometimes referred to as missing 
heritability. The size of this missing heritability is disputable since the size of the entire 
heritability of MS remains unclear. Probably gene-gene and gene-environment 
interactions as well as rare gene variants (which GWAS analyses do not detect) make 
up a substantial part of the missing heritability (182). These as well as individual 
genetic factors influencing disease need to be biologically understood in order to 
approach the goal of developing new treatments. Now is the time to use all the genetic 
knowledge we have acquired over the past five years and design clever functional 
studies. Only then can we make the progress Green et al expect and push the blue dots 
in Figure 15 towards their main purpose: to treat patients. 
 
The scope of this thesis spans from determining genetic associations (paper I), via 
functional studies (paper III) to investigating clinical and treatment consequences 
(paper II and paper IV). Although I am very satisfied and proud of the work we have 
done over the last 4 years, there are many more experiments I wish I had already 
carried out, a few are listed below. 
 
• For paper I, the reason behind the discrepancy between different reports needs 
to be thoroughly investigated. I think sub-division of the different patient 
cohorts by MS sub-phenotype (i.e. RRMS, SPMS, PPMS) is a good starting 
point. Furthermore an outside, unbiased critical statistical evaluation of how the 
p-values were calculated (assumptions of genetic homogeneity within cohorts, 
environmental exposures not accounted for etc.) would be very helpful to 
determine if there are false positives, false negatives, or simply differing 
approaches. Understanding the variation in results would not only be important 
from a historical perspective, but might help future GWAS attempts to be more 
fruitful and avoid pitfalls. 
 
• It will be interesting to see whether the trend of paper II persists: susceptibility 
linked genes not influencing clinical parameters. On a different note, perhaps 
the EDSS scale is too prone to inter-physician variability in assessment to be 
useful in determining clinical influence of alleles with moderate influence on 
risk. I would like to see correlative studies between disease severity and a more 
objective outcome measure than EDSS e.g. MRI lesion load carried out. 
 
• Paper III opens a lot of exciting possibilities for future experiments. First of all I 
would like to test IL-7 + sIL7Rα in an animal model of infection to see whether 
the IL7R*C allele can help in this setting. If so, that could explain its high allele 
frequency across different populations and ethnicities despite its involvement in 
autoimmunity.  
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• Since IL-7 is in clinical trials as a mediator of immune reconstitution after 
disease or treatment induced lymphopenia, a quick experiment to test sIL7Rα’s 
impact on IL-7 biology would be to genotype these patients for IL7R. Our 
results from paper III would predict that IL7R*T carriers have a weaker 
response to recombinant human IL-7 since they have reduced sIL7Rα levels, 
and hence will experience a sharper peak and drop in IL-7 concentrations.  
 
• sIL7Rα could potentially stabilize fluctuations in IL-7 levels as an indirect 
consequence of T-cell proliferation during an MS relapse. Since IL-7 is an 
important factor in the formation of immunologic memory, perhaps sIL7Rα 
ensures there is always a baseline IL-7 concentration capable of stimulating 
memory formation after a relapse. Particularly, CIS patients who do not develop 
MS would be interesting to genotype for IL7R and study more closely. Another 
way to approach the issue of memory would be to re-challenge an animal model 
(infect for infectious model or MOG for EAE model) and see if their responses 
differ based on injection with IL-7 alone or IL-7 + sIL7Rα (the hypothesis 
being that IL-7 + sIL7Rα injected animals reactivate their immunologic 
memory and hence have a stronger response than animals injected with IL-7 
alone).  
 
• To follow up paper IV I would like to go after the consequences of elevated IL-
7 in IFNβ treated patients. Particularly, T-cell expression of α4 integrin, Treg 
counts and T-cell activation status would be interesting targets.  
 
In conclusion, I have learned a lot over the past 4 years, and hopefully contributed a 
small piece to solving the MS-puzzle. In one of our first meetings, Dr. Crystal Mackall 
told me “This project might not lead to a cure for MS, but at least we will learn a lot 
about IL-7 biology”. In retrospect, I think she was spot on. 
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